These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9778086)

  • 21. Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: applicability to the practice of medicine in the United States.
    Cohen M; Ferguson JJ; Harrington RA
    Clin Cardiol; 1999 Oct; 22 Suppl 6(Suppl 6):VI2-12. PubMed ID: 10526702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
    Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
    Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
    Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
    Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
    Bosanquet N; Jönsson B; Fox KA
    Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
    Bosch X; Marrugat J
    Cochrane Database Syst Rev; 2001; (4):CD002130. PubMed ID: 11687143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
    Tcheng JE
    Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231
    [No Abstract]   [Full Text] [Related]  

  • 30. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.
    Stringer KA
    Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
    Newby LK
    Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
    Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 'I can see clearly now': a new view on the use of IV GP IIb/IIIa inhibitors in acute coronary syndromes.
    Antman EM
    Eur Heart J; 2002 Sep; 23(18):1408-11. PubMed ID: 12208217
    [No Abstract]   [Full Text] [Related]  

  • 34. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
    Boersma E; Harrington RA; Moliterno DJ; White H; Théroux P; Van de Werf F; de Torbal A; Armstrong PW; Wallentin LC; Wilcox RG; Simes J; Califf RM; Topol EJ; Simoons ML
    Lancet; 2002 Jan; 359(9302):189-98. PubMed ID: 11812552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contemporary view of the acute coronary syndromes.
    Moustapha A; Anderson HV
    J Invasive Cardiol; 2003 Feb; 15(2):71-9. PubMed ID: 12556619
    [No Abstract]   [Full Text] [Related]  

  • 36. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Labinaz M; Kilaru R; Pieper K; Marso SP; Kitt MM; Simoons ML; Califf RM; Topol EJ; Armstrong PW; Harrington RA
    Circulation; 2002 Jan; 105(3):322-7. PubMed ID: 11804987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis.
    Cannon CP
    Clin Cardiol; 1999 Aug; 22(8 Suppl):IV37-43. PubMed ID: 10492852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: initiate treatment early or wait for the catheterization laboratory?
    Harnick DJ; Vorchheimer DA
    Curr Cardiol Rep; 2001 Sep; 3(5):355-61. PubMed ID: 11504571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting.
    Gibler WB; Wilcox RG; Bode C; Castaigne AD; Delooz H; Elich D; Fox KA; Kereiakes DJ; Rupprecht H; Topol EJ
    Ann Emerg Med; 1998 Dec; 32(6):712-22. PubMed ID: 9832669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
    Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD;
    JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.